The results suggest that MM cells are particularly vulnerable targets of LTK inhibition and suggest that potential synergies may be favorable both in combination with existing therapies (PIs and SINE) and may provide additional MM-relevant inhibition for repurposed ALK inhibitors. The gene discussed is ALK; the disease is Miyoshi myopathy.